Spots Global Cancer Trial Database for recurrent childhood ependymoma

Every month we try and update this database with for recurrent childhood ependymoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	NCT00053963	Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi...	romidepsin	- 21 Years	National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors	NCT00513981	Brain and Centr... Sarcoma Unspecified Chi...	leucovorin calc... methotrexate mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma	NCT00006102	Brain and Centr... Lymphoma Neuroblastoma Retinoblastoma Sarcoma Unspecified Chi...	becatecarin	- 21 Years	National Cancer Institute (NCI)
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors	NCT00002647	Brain and Centr... Metastatic Canc...	verteporfin conventional su...	3 Years - 70 Years	National Cancer Institute (NCI)
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma	NCT00008008	Brain and Centr...	filgrastim sargramostim cyclophosphamid... thiotepa autologous bone... bone marrow abl... peripheral bloo...	-	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer	NCT00025558	Brain and Centr...	filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo...	1 Year - 49 Years	NYU Langone Health
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	NCT00069940	Brain and Centr... Gastrointestina... Sarcoma	sargramostim telomerase: 540...	2 Years -	Dana-Farber Cancer Institute
Ex Vivo Drug Sensitivity Testing and Mutation Profiling	NCT03860376	Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chil... Refractory Chil... Refractory Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro...		1 Day - 21 Years	Florida International University
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas	NCT00002753	Brain and Centr...	iodine I 131 mo...	3 Years -	Duke University
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	NCT00002608	Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma	cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera...	- 65 Years	National Cancer Institute (NCI)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors	NCT00003765	Brain and Centr...	O6-benzylguanin... carmustine	- 21 Years	National Cancer Institute (NCI)
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer	NCT00025558	Brain and Centr...	filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo...	1 Year - 49 Years	NYU Langone Health
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors	NCT00098761	Brain and Centr...	laromustine	- 21 Years	Pediatric Brain Tumor Consortium
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	NCT00381797	Childhood Cereb... Childhood Oligo... Childhood Spina... Recurrent Child... Recurrent Child... Recurrent Child...	Bevacizumab Fludeoxyglucose... Irinotecan Hydr...	- 21 Years	National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors	NCT00095940	Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona...	- 21 Years	National Cancer Institute (NCI)
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma	NCT00360854	Brain and Centr...	erlotinib hydro... mutation analys... polymorphism an... laboratory biom... pharmacological... radiation thera...	1 Year - 21 Years	National Cancer Institute (NCI)
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors	NCT00098761	Brain and Centr...	laromustine	- 21 Years	Pediatric Brain Tumor Consortium
Everolimus for Children With Recurrent or Progressive Ependymoma	NCT02155920	Recurrent Child...	Everolimus	2 Years - 21 Years	University of Texas Southwestern Medical Center
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma	NCT00074334	Brain and Centr...	TGFa-PE38 immun... conventional su...	3 Years - 21 Years	Pediatric Brain Tumor Consortium
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma	NCT00363272	Childhood Burki... Childhood Centr... Childhood Choro... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Unspecified Chi...	ispinesib laboratory biom... pharmacological...	1 Year - 21 Years	National Cancer Institute (NCI)
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors	NCT01158300	Brain and Centr...	VEGF inhibitor ...	3 Years - 21 Years	Pediatric Brain Tumor Consortium
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	NCT01132547	Cancer	cyproheptadine ... placebo	2 Years - 21 Years	University of South Florida
High-Dose Methotrexate in Treating Young Patients With Solid Tumors	NCT00513981	Brain and Centr... Sarcoma Unspecified Chi...	leucovorin calc... methotrexate mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors	NCT00095940	Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona...	- 21 Years	National Cancer Institute (NCI)
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors	NCT00006247	Brain and Centr...	semaxanib	- 21 Years	Pediatric Brain Tumor Consortium
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer	NCT00014573	Brain and Centr...	aldesleukin autologous tumo... filgrastim sargramostim therapeutic aut... carmustine cisplatin cyclophosphamid... paclitaxel autologous bone... conventional su... peripheral bloo...	- 65 Years	Barbara Ann Karmanos Cancer Institute
Cilengitide in Treating Children With Refractory Primary Brain Tumors	NCT00063973	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	cilengitide laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers	NCT00002752	Brain and Centr... Metastatic Canc...	iodine I 131 mo...	3 Years -	Duke University
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	NCT02194452	Acoustic Schwan... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Choroid P... Adult Craniopha... Adult Diffuse A... Adult Ependymob... Adult Ependymom... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Grade I M... Adult Grade II ... Adult Medullobl... Adult Meningeal... Adult Mixed Gli... Adult Myxopapil... Adult Oligodend... Adult Papillary... Adult Pilocytic... Adult Pineal Gl... Adult Pineoblas... Adult Pineocyto... Adult Subependy... Adult Subependy... Adult Supratent... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Supra... Meningeal Melan... Newly Diagnosed... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child...	gallium Ga 68-e... positron emissi... computed tomogr... laboratory biom...	6 Months - 29 Years	University of Iowa
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	NCT00053963	Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi...	romidepsin	- 21 Years	National Cancer Institute (NCI)
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma	NCT02359565	Constitutional ... Lynch Syndrome Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Diffu... Recurrent Medul... Refractory Brai... Refractory Diff... Refractory Epen... Refractory Medu...	Biospecimen Col... Conventional Ma... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Dynamic Suscept... Magnetic Resona... Pembrolizumab	1 Year - 30 Years	National Cancer Institute (NCI)
Etoposide in Treating Young Patients With Relapsed Ependymoma	NCT00278252	Brain and Centr...	etoposide conventional su...	- 21 Years	National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	NCT00069940	Brain and Centr... Gastrointestina... Sarcoma	sargramostim telomerase: 540...	2 Years -	Dana-Farber Cancer Institute
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors	NCT00238173	Bone Marrow Sup... Brain and Centr... Drug/Agent Toxi... Long-term Effec...	filgrastim acetylcysteine carboplatin cyclophosphamid... etoposide phosp... mannitol sodium thiosulf...	1 Year - 18 Years	OHSU Knight Cancer Institute
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma	NCT00008008	Brain and Centr...	filgrastim sargramostim cyclophosphamid... thiotepa autologous bone... bone marrow abl... peripheral bloo...	-	National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: